Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy

Lüftner, Diana; Dell’Acqua, V.; Selle, Frédèric; Khalil, Ahmed; Dicuonzo, Samantha; Tomás, A. de La Torre; Shenouda, George; Fernández, J. Romero; Orecchia, Roberto; Moyal, Dominique; Seité, Sophie

doi:10.2147/ott.s155438

Cited by 12 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Not only do those skin disorders make it difficult to continue treatment, they can also cause impairment of the patient's quality of life [10][11][12][13][14][15][16][17][18][19]. Therefore, when using anticancer drugs with skin toxicity, prevention, early detection and treatment of skin disorders are essential [11,13,20,21].…”

Section: Discussionmentioning

confidence: 99%

Hand Foot Syndrome Has the Strongest Impact on QOL in Skin Toxicities of Chemotherapy

Urakawa¹,

Tarutani²,

Kubota³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Background: Chemotherapy often results in dermatologic toxicities, which decrease quality of life (QOL) of cancer patients. These adverse skin reactions sometimes happen simultaneously. Though previous reports have demonstrated that skin reactions influence QOL, those reports were focused on only one kind of skin toxicity or on the most serious skin toxicity. The aim of this study is to demonstrate the contribution of each skin toxicity to QOL. Methods: This is a cross-sectional study at Kinki Central Hospital. Patients were enrolled who underwent skin toxic chemotherapy from April 1 to June 30, 2017. DLQI and Skindex29 were used to grade the QOL of patients. Also, the severity of skin toxicities was evaluated based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE ver4.0). We investigated how QOL changed with patient demographic and clinical characteristics, the worst skin toxicity grade, and each skin toxicity using statistical analyses. Results: No significant differences were detected between QOL scores (total score of DLQI, emotions domain, symptoms domain, functioning domain and total score of Skindex29) and patient demographic and clinical characteristics (P values were 0.155, 0.086, 0.052, 0.312 and 0.114, respectively). There were statistically significant QOL differences among the grades of the worst skin toxicity (P values were <0.001). Xerosis, paronycia, pigmentation, and hand foot syndrome showed statistically significant associations with some QOL domains analyzed by multiple logistic regression analyses adjusted by demographic characteristics. When adjusted by both demographic characteristics and other skin toxicities, three of xerosis, paronycia, and pigmentation showed no statistically significant associations, but hand foot syndrome showed statistically significant associations in all subdomains and total score of Skindex29 (P values were <0.05). Conclusions: Hand foot syndrome was a stronger factor in decreasing QOL than xerosis, paronychia, pigmentation, or rash. Therefore, especially in hand foot syndrome, prevention, early detection, and daily medical care are necessary to maintain QOL.

show abstract

Section: Discussionmentioning

confidence: 99%

Hand Foot Syndrome Has the Strongest Impact on QOL in Skin Toxicities of Chemotherapy

Urakawa¹,

Tarutani²,

Kubota³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

show abstract

“…47 Lüftner et al (2018) conducted a multicenter prospective observational open-label study to evaluate the use of a 12-product kit for fifty patients receiving chemotherapy who received skincare kits before starting their cancer treatment with instructions to use the skincare throughout the treatment phase. 48 The study indicated skincare benefits, helping to M.E. Lacouture, J. Choi, A. Ho, J. Leventhal, et al minimize cAEs and improving the skin condition such as edema, erythema, dryness, desquamation, pigmentation disorders, and cracks.…”

Section: Skincare Benefits For Caes Statement 4: When Acute Cutaneous Reactions Develop Effective Skincare Should Be Reinforced To Reducementioning

confidence: 92%

“…Lacouture, J. Choi, A. Ho, J. Leventhal, et al minimize cAEs and improving the skin condition such as edema, erythema, dryness, desquamation, pigmentation disorders, and cracks. 48…”

Section: Skincare Benefits For Caes Statement 4: When Acute Cutaneous Reactions Develop Effective Skincare Should Be Reinforced To Reducementioning

confidence: 99%

“…Lacouture, J. Choi, A. Ho, J. Leventhal, et al includes skin hygiene, moisturization, sun protection, and, if applicable, camouflage products (Table 4). [46][47][48]50 Statement 8: Skin cleansing, skin hydration, and photoprotection should be considered in cancer patients and survivors to prevent and manage cutaneous side effects before, during, and after cancer therapy.…”

Section: Photo-protectionmentioning

confidence: 99%

See 1 more Smart Citation

US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm

Lacouture¹,

Choi²,

Ho³

et al. 2021

JDD

View full text Add to dashboard Cite

Background: An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients' quality of life and interrupt anticancer treatment. The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients' and survivors' quality of life by offering tools for preventing and managing cAEs. Methods: An algorithm was designed to reduce the incidence of cAEs, treat cAEs, and maintain healthy skin using general measures and over-the-counter agents to support all healthcare providers treating oncology patients, including physicians, nurses, pharmacists, and advanced providers. The panel used a modified Delphi approach, developed, discussed, and reached a consensus on statements and an evidence-based algorithm. Results:The USCOM algorithm includes education on cAEs for patients and clinicians supporting prevention, treatment, and maintenance using skincare measures before, during, and after cancer treatment. A skincare regimen including hygiene, moisturization, and sun protection products should be safe and effective in helping to minimize cAEs and improving skin conditions such as erythema, xerosis, pruritus, and photosensitivity. The number and quality of studies evaluating skincare formulations and regimens for cAEs are increasing, but the evidence on the benefits of specific formulations is still scarce. Conclusions: The algorithm focuses on general measures and skincare to prevent or reduce the severity of cAEs. Increased awareness of cAEs by the multidisciplinary team treating and guiding the cancer patient throughout their care may improve patient outcomes.

show abstract

“…12 A board of experts recommended the use of clinically tested skin care interventions to manage cutaneous reactions prior to, during, and after cancer therapy 13 . However, the evidence on interventions such as urea-based cream 14 or uorouracil 5% cream 15 is limited by the studies that lacked a control group, by the focus on targeted therapy, or by the simultaneous use of multiple products 16,17 , so that it was unclear which individual product was bene cial. Moreover, there is no randomized evidence evaluating the e cacy of any tailored intervention for managing speci c skin problems such as chemotherapy-induced dryness.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of a Tailored Moisturizer for Reducing Chemotherapy-Induced Skin Dryness in Breast Cancer Patients: A Randomized Controlled Trial

Kang

Kim

et al. 2021

Preprint

View full text Add to dashboard Cite

Introduction: While up to 60% of breast cancer patients undergoing chemotherapy experience skin side effects reducing quality of life, it was unclear which individual product was beneficial. To evaluate the effectiveness of a tailored moisturizer with a high content (1.5%) of pseudo-ceramides on skin dryness due to chemotherapy in breast cancer patients. Methods: Randomized controlled trial conducted from February 2015 to October 2018. 204 breast cancer patients experiencing skin dryness after 1 cycle of chemotherapy were randomly assigned to 3 groups (tailored moisturizer with high pseudo-ceramide content; general moisturizer; and usual care). Skin dryness, dullness, quality of life, and changes in sebum level were assessed at baseline, 3 weeks, and 1 month after completion of chemotherapy. The primary objective of the trial was to compare the tailored moisturizer group to usual care.Results: At 1 month after completion of chemotherapy, the tailored moisturizer group was significantly less likely to report severe skin dryness compared to the usual care group (8.5 vs. 27.9%, respectively, P < 0.01). The tailored moisturizer group reported significantly lower levels of skin dullness and lower levels of impairment of dermatological quality of life compared with the other two groups. Conclusions: A tailored moisturizer with a high content of pseudo-ceramides improved skin dryness, dullness and dermatological quality of life compared to usual care in breast cancer patients undergoing chemotherapy.

show abstract

Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy

Cited by 12 publications

References 20 publications

Hand Foot Syndrome Has the Strongest Impact on QOL in Skin Toxicities of Chemotherapy

Hand Foot Syndrome Has the Strongest Impact on QOL in Skin Toxicities of Chemotherapy

US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm

Efficacy of a Tailored Moisturizer for Reducing Chemotherapy-Induced Skin Dryness in Breast Cancer Patients: A Randomized Controlled Trial

Contact Info

Product

Resources

About